These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
3. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease. Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886 [TBL] [Abstract][Full Text] [Related]
4. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft. Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494 [TBL] [Abstract][Full Text] [Related]
5. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation. Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552 [TBL] [Abstract][Full Text] [Related]
6. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen. Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557 [TBL] [Abstract][Full Text] [Related]
7. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285 [TBL] [Abstract][Full Text] [Related]
8. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease? Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E; Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175 [TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218 [TBL] [Abstract][Full Text] [Related]
10. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907 [TBL] [Abstract][Full Text] [Related]
11. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715 [TBL] [Abstract][Full Text] [Related]
13. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680 [TBL] [Abstract][Full Text] [Related]
14. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes. Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; Moreno-Lafont M; García-Latorre E; Ramírez-Sanjuan E; Montiel-Cervantes L; Tripp-Villanueva F; García-León LD; Ayala-Sánchez M; Rosas-Cabral A; Aviña-Zubieta JA; Galindo-Rodríguez G; Vadillo-Buenfil M; Salazar-Exaire D Ann Hematol; 2004 May; 83(5):295-301. PubMed ID: 15060749 [TBL] [Abstract][Full Text] [Related]
15. Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine. Görner M; Kordelas L; Thalheimer M; Luft T; Pfeiffer S; Ustaoglu F; Punzel M; Weber-Nordt R; Moos M; Goldschmidt H; Ho AD Bone Marrow Transplant; 2002 Apr; 29(7):621-4. PubMed ID: 11979314 [TBL] [Abstract][Full Text] [Related]
16. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440 [TBL] [Abstract][Full Text] [Related]